Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director, Oncology Commercial Data Science & AI Products
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Gaithersburg - MD
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
We're building a connected, end-to-end Enterprise AI engine - uniting data foundations, AI technology, process reinvention, and business-facing AI to accelerate results across the whole value chain. Success depends on being exceptional connectors: you'll actively leverage existing capabilities, celebrate and promote reuse, export breakthrough ideas across geographies and functions, and obsess over scaling impact rather than building in isolation. If you thrive in high-collaboration environments where your role is to turn complex, cross-functional problems into reusable, enterprise-wide capabilities - and where the measure of success is adoption and scale, not just innovation - you'll have the platform (and sponsorship) to make it real. Our DS&AI Products team is the OBU's in-house engine for that work. We lead all aspects of the full lifecycle of AI-powered applications spanning predictive field triggers, patient-identification models, omnichannel next-best-action, KOL intelligence, and GenAI-powered field tools — and we ship products, not reports. Every capability we build must deliver measurable field adoption and commercial impact. We are hiring a Director, DS&AI Products who will lead a multi-indication AI product portfolio end-to-end, serve as the strategic DS&AI business partner to OBU brand and medical leadership, and lead the responsible design, delivery, adoption, and impact measurement of AI solutions that drive commercial lift and better patient outcomes. Role overview This is a product ownership and program strategy role — not an analytics consulting role. You lead the full AI product lifecycle: problem definition, customer research, product requirements, AI development partnership, UX design alignment, deployment, change management, and post-launch impact measurement. You are the product owner and strategist for the AI capabilities powering Sales, Marketing, and Medical Affairs across your assigned OBU tumor areas, and the liaison US Oncology and the broader AstraZeneca Enterprise AI organization for customer engagement capability building. You will be equally comfortable writing a product requirements document, reviewing a GenAI architecture with an engineering lead, running a discovery session with brand managers, delivering the AI transformation narrative to field sales leadership and presenting a capability roadmap to the Senior Leadership Teams. You will bring a platform-centric, reuse-first mindset: every solution you ship should be architected for scalability and accelerated deployment across indications - so a trigger framework proven in one tumor area becomes the template for the next launch. Key responsibilities 1. Program Strategy & AI Roadmap Ownership • Own the strategy and transformation roadmap for Sales, Marketing, and Medical Affairs AI capabilities across your assigned OBU tumor-area portfolio, being responsible for planning and budget management processes in alignment with OBU annual cycle. • Develop quantifiable cases and value narratives for future Sales, Marketing, and field AI capabilities in collaboration with OBU Franchises, I&A, and Enterprise AI delivery teams; present to OBU Leadership Team (OLT) to drive top-down alignment and shared decisions on roadmap prioritization. • Maintain a prioritized product backlog with well-defined user stories, acceptance criteria, and delivery timelines; balance the portfolio across housekeeping (maintenance/refresh), innovation (new AI capability pilots), and new-indication onboarding in an agile operating model. • Track industry, market, and innovation shifts — GenAI, agentic AI, oncology data science, competitor AI strategies — to anticipate opportunities and risks and keep the roadmap